Literature DB >> 1557956

Neuropathologic findings in cortical resections (including hemispherectomies) performed for the treatment of intractable childhood epilepsy.

M A Farrell1, M J DeRosa, J G Curran, D L Secor, M E Cornford, Y G Comair, W J Peacock, W D Shields, H V Vinters.   

Abstract

Despite the use of hemispherectomy in the treatment of medically refractory seizures since the early 1950's, few studies published have documented neuropathologic findings in the resected specimens. This report describes the neuropathologic findings in 38 children who underwent either hemispherectomy or multilobar cortical resection as treatment for medically intractable epilepsy between 1986 and 1990. Examination of the resected specimens revealed a variety of abnormalities which fell into four broad categories. Malformations or hamartomatous lesions were the dominant finding in 15 patients, whereas encephalomalacic lesions were the most prominent abnormality in 16; chronic pathogen-free encephalitits (Rasmussen's encephalitis) was present in 3 and an additional 3 children had Sturge-Weber-Dimitri syndrome. There were no gross or microscopic abnormalities in 1 patient. This report provides the first comprehensive description of the pathologic findings in a series of children with refractory epilepsy of varying types treated by hemispherectomy-multilobar resection.

Entities:  

Mesh:

Year:  1992        PMID: 1557956     DOI: 10.1007/bf00296786

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  64 in total

1.  Cerebral hemispherectomy for control of intractable convulsive seizures.

Authors:  L A FRENCH; D R JOHNSON; I A BROWN; F B VAN BERGEN
Journal:  J Neurosurg       Date:  1955-03       Impact factor: 5.115

2.  Treatment of encephalotrigeminal angiomatosis (Sturge-Weber disease) by hemispherectomy.

Authors:  M A FALCONER; R G RUSHWORTH
Journal:  Arch Dis Child       Date:  1960-10       Impact factor: 3.791

3.  Cerebral hemispherectomy: present status and clinical indications.

Authors:  R J GOODALL
Journal:  Neurology       Date:  1957-03       Impact factor: 9.910

4.  Patterns of cerebral arterial injury in children with neurological disabilities.

Authors:  R J Baumann; W A Carr; R M Shuman
Journal:  J Child Neurol       Date:  1987-10       Impact factor: 1.987

5.  Hemispherectomy in children.

Authors:  E B Hendrick; H J Hoffman; A R Hudson
Journal:  Clin Neurosurg       Date:  1969

6.  Unilateral megalencephaly: correlation of MR imaging and pathologic characteristics.

Authors:  A J Barkovich; S H Chuang
Journal:  AJNR Am J Neuroradiol       Date:  1990-05       Impact factor: 3.825

7.  Infantile spasms: I. PET identifies focal cortical dysgenesis in cryptogenic cases for surgical treatment.

Authors:  H T Chugani; W D Shields; D A Shewmon; D M Olson; M E Phelps; W J Peacock
Journal:  Ann Neurol       Date:  1990-04       Impact factor: 10.422

8.  Pathology of temporal lobe foci: correlation with CT, MRI, and PET.

Authors:  W H Theodore; D Katz; C Kufta; S Sato; N Patronas; P Smothers; E Bromfield
Journal:  Neurology       Date:  1990-05       Impact factor: 9.910

9.  Functional hemispherectomy for treatment of epilepsy associated with hemiplegia: rationale, indications, results, and comparison with callosotomy.

Authors:  P Tinuper; F Andermann; J G Villemure; T B Rasmussen; L F Quesney
Journal:  Ann Neurol       Date:  1988-07       Impact factor: 10.422

10.  Hemimegalencephaly: a clinicopathological study of four cases.

Authors:  O Robain; C Floquet; N Heldt; F Rozenberg
Journal:  Neuropathol Appl Neurobiol       Date:  1988 Mar-Apr       Impact factor: 8.090

View more
  27 in total

1.  Utility of Tc 99m HMPAO SPECT in the early diagnosis of Rasmussen's syndrome.

Authors:  F Paladin; G Capovilla; A Bonazza; R Mameli
Journal:  Ital J Neurol Sci       Date:  1998-08

2.  Neuropathologic findings in surgically treated hemimegalencephaly: immunohistochemical, morphometric, and ultrastructural study.

Authors:  M J De Rosa; D L Secor; M Barsom; R S Fisher; H V Vinters
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

Review 3.  Stem cells as a potential therapy for epilepsy.

Authors:  Steven N Roper; Dennis A Steindler
Journal:  Exp Neurol       Date:  2012-01-13       Impact factor: 5.330

4.  Decreased glutamate transport enhances excitability in a rat model of cortical dysplasia.

Authors:  Susan L Campbell; John J Hablitz
Journal:  Neurobiol Dis       Date:  2008-07-15       Impact factor: 5.996

Review 5.  Polarity regulation in migrating neurons in the cortex.

Authors:  Orly Reiner; Tamar Sapir
Journal:  Mol Neurobiol       Date:  2009-03-28       Impact factor: 5.590

6.  Enhanced GABAergic network and receptor function in pediatric cortical dysplasia Type IIB compared with Tuberous Sclerosis Complex.

Authors:  Carlos Cepeda; Véronique M André; Jason S Hauptman; Irene Yamazaki; My N Huynh; Julia W Chang; Jane Y Chen; Robin S Fisher; Harry V Vinters; Michael S Levine; Gary W Mathern
Journal:  Neurobiol Dis       Date:  2011-08-23       Impact factor: 5.996

Review 7.  Mechanisms of epileptogenesis in pediatric epileptic syndromes: Rasmussen encephalitis, infantile spasms, and febrile infection-related epilepsy syndrome (FIRES).

Authors:  Carlos A Pardo; Rima Nabbout; Aristea S Galanopoulou
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

8.  Chronic encephalitis associated with epilepsy: immunohistochemical and ultrastructural studies.

Authors:  M A Farrell; O Droogan; D L Secor; V Poukens; B Quinn; H V Vinters
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

9.  Management of refractory complex partial seizures: current state of the art.

Authors:  David M Treiman
Journal:  Neuropsychiatr Dis Treat       Date:  2010-06-24       Impact factor: 2.570

10.  Glial and neuronoglial malformative lesions associated with medically intractable epilepsy.

Authors:  A Vital; C Marchal; H Loiseau; A Rougier; J M Pedespan; J Rivel; C Vital
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.